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Background: Relatively poor penetration and retention in tumor tissue has been documented for large molecule
drugs including therapeutic antibodies and recombinant immunoglobulin constant region (Fc)-fusion proteins due
to their large size, positive charge, and strong target binding affinity. Therefore, when designing a large molecular
drug candidate, smaller size, neutral charge, and optimal affinity should be considered.
Methods: We engineered a recombinant protein by molecular engineering the second domain of VEGFR1 and a
few flanking residues fused with the Fc fragment of human IgG1, which we named HB-002.1. This recombinant
protein was extensively characterized both in vitro and in vivo for its target-binding and target-blocking activities,
pharmacokinetic profile, angiogenesis inhibition activity, and anti-tumor therapeutic efficacy.
Results: HB-002.1 has a molecular weight of ~80 kDa, isoelectric point of ~6.7, and an optimal target binding
affinity of <1 nM. The pharmacokinetic profile was excellent with a half-life of 5 days, maximal concentration of
20.27 μg/ml, and area under the curve of 81.46 μg · days/ml. When tested in a transgenic zebrafish embryonic
angiogenesis model, dramatic inhibition in angiogenesis was exhibited by a markedly reduced number of subintestinal
vessels. When tested for anti-tumor efficacy, HB-002.1 was confirmed in two xenograft tumor models (A549 and
Colo-205) to have a robust tumor killing activity, showing a percentage of inhibition over 90% at the dose of
20 mg/kg. Most promisingly, HB-002.1 showed a superior therapeutic efficacy compared to bevacizumab in the
A549 xenograft model (tumor inhibition: 84.7% for HB-002.1 versus 67.6% for bevacizumab, P < 0.0001).
Conclusions: HB-002.1 is a strong angiogenesis inhibitor that has the potential to be a novel promising drug for
angiogenesis-related diseases such as tumor neoplasms and age-related macular degeneration.
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Targeted tumor therapy is the focus of recent intense
drug development by the pharmaceutical industry with
the primary interests centered on antibody drugs [1].
However antibody and/or recombinant protein drugs
with molecular weights (MWs) of over 100 kDa usually
have relatively poor tumor penetration and retention
capacity for which the molecular size, charge, as well as
target binding affinity play important roles [2]. There are* Correspondence: tian110602@huabobio.com
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mors due to disordered vasculature, tissue structure, as
well as extracellular matrix (ECM). These factors, which
impact penetration and retention of large molecule
drugs, have to be considered when designing new mo-
lecular constructs.
Angiogenesis, the process by which the existing vascular
network expands to form new blood vessels, is mainly me-
diated by vascular endothelial growth factor (VEGF),
which upon binding with VEGF receptor (VEGFR), can in-
duce phosphorylation of the receptors expressed in the
blood vessel endothelial cells [1], thus leading to prolifera-
tion of the endothelial cells and the development of thes is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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and other members of the VEGF family including placen-
tal growth factor (PlGF) are upregulated [3-6]. Among the
factors contributing to angiogenesis, VEGF-A is the main
ligand driving angiogenesis, making it an important target
for drug development.
Several drugs targeting VEGF have been approved for
use in the treatment of cancer [7] as well as for wet age-
related macular degeneration (AMD) [8]. Bevacizumab is
a humanized antibody targeting VEGF-A and was ap-
proved under the trade name of Avastin in 2004 for the
treatment of metastatic colon cancer [9-11] as well as sev-
eral other solid tumors including lung cancers [12,13],
glioblastoma [14,15], renal cancers [16], and ovarian can-
cers [17-19]. The main mechanism by which bevacizumab
exerts anti-tumor activity is by preventing VEGF-A from
binding with its receptors, thus resulting in inhibition of
new blood vessel growth in tumor tissues. Bevacizumab is
a humanized IgG1 with over 90% of human and less than
10% of murine components [20]. The recommended dose
for bevacizumab is 5 mg/kg every 2 weeks, even though it
could be detected in serum for 12 weeks [21]. Bevacizu-
mab is the first VEGF blocker proven to improve survival
by 30% in patients with metastatic colorectal cancer
[22]. However due to target limitation (only targeting
VEGF-A) as well as relatively poor tissue penetration
because of its large size, the overall impact of bevacizu-
mab in prolonging survival was very limited [22,23],
with 5-year survival generally between 5% and 8% [23],
suggesting that VEGF-A blockade alone may not be
good enough to completely prevent tumor angiogenesis
and corresponding tumor growth.
Aflibercept (originally called VEGF-Trap) was approved
in August of 2012 under the trade name of Zaltrap for the
treatment of metastatic colon cancer, and the same mol-
ecule was approved in November of 2011 under the trade
name of Eylea for the treatment of AMD. Aflibercept is a
recombinant fusion protein consisting of the second im-
munoglobulin (Ig) domain of VEGFR1 and the third Ig
domain of VEGFR2, fused to the immunoglobulin con-
stant region (Fc) portion of human IgG1 [24]. Unlike bev-
acizumab, aflibercept exhibits affinity for all isoforms of
VEGF and PlGF [25] and exerts robust antivascular ef-
fects by rapid regression of existing tumor vessels [26],
normalization of surviving mature vessels [27], and in-
hibition of new tumor vessel growth [28]. The anti-tumor
efficacy of aflibercept has been confirmed in several solid
tumor models, all demonstrating effective tumor inhib-
ition [29]. Aflibercept has a MW of 110 kDa and has a
half-life in plasma of 4-5 days [24]. The clinical benefits
for aflibercept treatment of metastatic colon cancer pa-
tients are similar to bevacizumab [30].
It has been documented that the VEGF-binding affin-
ity of VEGFR1 is 10 fold higher than that of VEGFR2[31] and the second Ig domain of VEGFR1 is critical for
VEGF binding [32]. We reasoned that a recombinant
protein composed of only the second domain (D2) of
VEGFR1 might retain sufficient VEGF binding, but also
have better bioavailability and penetration properties
due to its smaller size as compared to the previously de-
scribed current generation of drugs that block VEGF.
We therefore designed an expression vector that
expressed a recombinant protein consisting of the D2
portion of VEGFR1 fused with the Fc portion of human
IgG1. This protein was extensively characterized for its
target-binding affinity, angiogenesis inhibition, and phar-
macokinetic (PK) profile, as well as for its anti-tumor ef-
ficacy in several xenograft tumor models.
Methods
Engineering of recombinant proteins
HB-002.1 is a recombinant protein consisting of two com-
ponents: one is the D2 domain of human VEGFR1 (Flt1)
(P134-T226) plus 5 (S129-R133) and 2 (N227, T228)
amino acids of upstream and downstream flanking se-
quence respectively, and the second is the Fc fragment of
human IgG1. To construct the HB-002.1 expression vec-
tor, 57 nucleotides encoding the signal peptide of mouse
IgG1 heavy chain were added to the 5' end of VEGFR1-
D2, a Kozak sequence was added to the 5' end of the
signal peptide sequence, and cloning sites, HindIII and
EcoRI, were added to the 5' and 3' ends of the resulting
sequence, respectively. This designed D2 expression cassette
sequence was synthesized (GenScript) and subcloned
into the HindIII and EcoRI sites of the pHB-Fc vector
(Generay, ID: X9913T).
The recombinant Flt1[2]-Fc protein contains the
VEGFR1-D2 domain (P134-T226) without the addition
of flanking region amino acids, plus the Fc fragment of
human IgG1.
All recombinant proteins were expressed and purified
from Chinese hamster ovary (CHO) cells (Cat# CCL-61,
ATCC). 5 μg of each protein were loaded on 10% SDS-
PAGE gels under reducing as well as non-reducing con-
ditions. Gels were stained with 0.3% Coomassie Brilliant
Blue R-250 and destained with 20% methanol.
Western blotting and digestion of proteins with
N-glycosidase F
To validate the identity of the purified protein, Western
blotting analysis was performed [33]. Briefly, different
amounts of the purified protein (1, 0.5, 0.25 μg) were sepa-
rated by electrophoresis in 4-12% Bis-Tris protein gels, and
then transferred to a polyvinylidene difluoride membrane.
The membrane was probed using antibodies specific either
for Fc fragment (horseradish peroxidase (HRP)-conjugated
rabbit F(ab’)2 anti-human IgG, Fc-fragment specific (Immu-
noResearch Lab) or HRP*Polyclonal Rabbit Anti-Human
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for human VEGFR1 (Cat# 10136-RP02, Sino Biological Inc)
followed by incubation with secondary antibody (HRP-con-
jugated Affinipure F(ab')2 Fragment Goat Anti Rabbit
IgG1, F(ab')2 Fragment Specific (ImmunoResearch Lab)).
Specific bands were visualized via the ECL kit according to
the manufacturer’s instructions (Amersham).
To analyze the impact of glycosylation on protein activ-
ity, HB-002.1 protein (Lot#20130521, 3.62 mg/ml) diluted
to 0.5 mg/ml in 100 mM of ammonium bicarbonate was
incubated with N-glycosidase F (Cat#11365193001, Sigma)
(5 Unit/10 μg protein) at 37°C for 18 hours. Digested and
non-digested proteins were analyzed in 12% SDS-PAGE
under reducing and non-reducing conditions. In parallel,
the digested protein was also assayed for target binding ac-
tivity, which was compared to that of the parental protein.
Target-binding assay
Target binding affinity of HB-002.1 was measured by
ELISA in Falcon 96-Well ELISA Micro Plates coated
overnight at room temperature with VEGF ligands or
PIGF (R&D Systems) in PBS (100 ng per well). Coated
plates were blocked with 3% dry fat milk in PBS-T buffer
(PBS containing 0.05% Tween-20) and then 100 μl of
serially diluted HB-002.1 or bevacizumab (Lot#:N3526,
Roche) or hIgG-Fc (Cat#:10702-HNAH, Sino Biological
Inc) (from 5 nM to 0.0024 nM) were transferred into the
plates. After incubation at room temperature for 1 hour,
plates were washed 5 times with PBS-T solution, and
then incubated with HRP-conjugated Fc-specific anti-
body (Cat#C030222, Cellway-Lab, Luoyang, China) at
room temperature for 1 hour. Plates were washed 5 times
with PBS-T buffer and then developed with 100 μl of
HRP-substrate solution for up to 5 minutes. The reaction
was stopped with 1 N H2SO4, and the absorbance at 450
nM was determined in a standard plate reader.
To determine the kinetic target binding affinity of HB-
002.1, varying amounts of VEGF-A were mixed with 0.5
nM of HB-002.1, Flt1[2]-Fc, hIgG-Fc or bevacizumab and
then incubated for 2 hours at room temperature. The mix-
tures were transferred to VEGF-A coated plates and in-
cubated for 1 hour at room temperature, the non-bound
proteins in solution were washed away, and the amounts
of HB-002.1, Flt1[2]-Fc, hIgG-Fc or bevacizumab bound
to the plates were measured by HRP-conjugated rabbit
anti-human IgG-Fc antibody. The kinetic binding affinities
were analyzed according to the amounts of free VEGF
blocker in the mixtures.
VEGFR2 phosphorylation assay
4 ml of human umbilical vein endothelial cells (HUVECs)
(Cat#HUVEC-004, ALLCELLS) in complete HUVEC-
adapted medium (Cat#H-004, ALLCELLS) were incubated
in 6 cm dishes at 37°C, 5% CO2 for 24 hours, cells werestarved for 2 hours and then challenged for 15 minutes
with either medium alone, or VEGF-A (20 ng/ml) only, or
VEGF-A pre-incubated with varying amounts of HB-
002.1. Cells were washed twice with cold PBS and then
dissolved in 200 μl of lysis buffer (50 mM Tris, pH 7.4, 1%
sodium deoxycholate, 1% Triton X-100, 0.1% SDS, 1 mM
EDTA, pH 8.0, 150 mM NaCl). After centrifugation and
quantitation, equal amounts of supernatant from each
sample were subjected to Western blotting analysis using
antibodies specific either for total VEGFR2 (Cat# 2479,
Cell Signaling Technology) or for VEGFR2 phosphotyro-
sine (Cat# 3770S, Cell Signaling Technology).
VEGF-induced HUVEC proliferation and tube formation
assay
HUVEC proliferation in response to VEGF-A and the
impact of HB-002.1 on cell proliferation was measured
using CCK-8 kits (Cat# CK04-11, DOJINDO Laborator-
ies) following the manufacturer's instructions. Briefly,
2000 HUVECs per well were plated in a 96-well plate,
which was incubated at 37°C for 2 hours. 100 μl of re-
agent solution containing 20 ng/ml of VEGF-A and
varying amounts of HB-002.1, bevacizumab or hIgG-Fc
were transferred to the plate. Cells were cultured for
72 hours at 37°C, and then CCK-8 was added to these
cultures, which were incubated for 4 additional hours
followed by spectrophotometric analysis at 450 nm.
The VEGF-induced tube formation assay was conducted
as previously described [34]. Briefly, 50 μl of HUVECs at 3
× 105/ml in culture medium were mixed with 50 μl of cul-
ture medium containing 20 ng/ml of VEGF-A plus 1000
nM HB-002.1 protein, bevacizumab or control human
IgG. The mixtures were added to 96-well plates contain-
ing 50 μl of solidified Matrigel. Plates were incubated in a
cell culture incubator at 37°C for 24 hours. Tube forma-
tion was observed using an inverted phase contrast micro-
scope (Eclipse TS100, Nikon). Images were captured with
a CCD color camera (KP-D20AU, Hitachi) attached to the
microscope using 40x magnification plus 1.5x amplifica-
tion by the CCD camera. The tube length in three differ-
ent fields was measured using Image-Pro Plus software
(Version 6.0, Media Cybernetics).
Angiogenesis analysis
The impact of HB-002.1 on angiogenesis was investigated
using a transgenic zebrafish embryonic angiogenesis model
[35]. Briefly, the tested protein or control drugs were
microinjected into the common cardinal vein of zebrafish
at 48 hours post-fertilization (hpf). The subintestinal vessels
(SIVs) were visualized under a Multi-Purpose Zoom Micro-
scope (Nikon AZ100), and the area of the SIVs at 72 hpf
was measured as mean fluoresence intensity (MFI) using
NIS-Elements D imaging software. The percentage of
angiogenesis inhibition was calculated as (MFI of vehicle
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treated SIVs x 100.
Pharmacokinetic analysis
16 BALB/c mice (female, age of 4-5 weeks, body weight
of 18-20 g) received a subcutaneous (s.c.) injection of
50 μg HB-002.1 protein (~2.5 mg/kg mouse) and bled at
1, 2, 4, 6, 24, 48, 72, and 144 hours after injection. Levels
of HB-002.1 in the plasma were measured by ELISA
assay using human VEGF165 (R&D Systems) as capture
protein and HRP-anti-human Fc (Jackson ImmunoRe-
search Lab) as the detection antibody.
In vivo efficacy study
Mouse xenograft tumor models using human Colo-205
and A549 cancer cells were applied to the investigation
of the in vivo efficacy of HB-002.1. Cells purchased from
ATCC were resuspended in serum-free medium. BALB/c
nude mice were ordered from Shanghai SLAC Laboratory
Animal Co. Ltd. The animals were specific pathogen free
and approximately 4 - 5 weeks old upon arrival at Phar-
maLegacy Laboratories. The procedures that were applied
to animals in this protocol had been approved by Pharma-
Legacy Laboratories IACUC before the execution of the
study. Approximately 5 × 106 cells in 200 μl of serum-free
medium/matrigel (50:50 v/v) were injected s.c. in the right
flank of each of the 70 mice for each model under
anesthesia by 3 - 4% isoflurane. When the average tumor
volume reached 100 - 200 mm3, 50 mice bearing tumors
of suitable size were randomized into 5 groups (10 mice
per group) according to tumor volume and body weight.
Mice were treated with two different doses (5 mg/kg,
20 mg/kg) of HB-002.1 or control drugs by intraperitoneal
(i.p.) injections twice weekly for four weeks except for
doxorubicin which was given only in one injection. Tumor
volume and body weight were measured twice a week
until the termination of the study. Tumor growth inhib-
ition (TGI%) = (1-(change in mean treated tumor volume/
change in mean control untreated tumor volume)) × 100.
Tumor weight measured at time of mice sacrifice.
Histology analysis
Tumors were harvested and sectioned at the end of the ex-
periments. Tumor sections were subsequently dewaxed
and rehydrated. After quenching endogenous peroxidase
activity, sections were immunohistochemically stained with
respective antibody. Stained sections were dehydrated in
alcohol and xylene, and then mounted. The procedure for
hematoxylin and eosin (H&E) staining of tumor sections
was as follows: dewaxing in xylene, gradient ethanol dehy-
dration, hematoxylin staining, rinsing with tap water, coun-
terstaining with eosin, rinsing with ethanol, gradient
ethanol dehydration, and vitrification with xylene. Immu-
nohistochemical staining was performed using antibodiesspecific for CD31 (Cat#: ab9498, Abcam) followed by goat
anti-mouse secondary antibody (Cat#: KIT5002, Fuzhou
Maixim) and goat anti-rabbit secondary antibody (Cat#:
KIT5005, Fuzhou Maixim), respectively. The microvessel
density was quantified by the visual approximation tech-
nique, which involved manual counting vessels in three
different microscope fields at 10x magnification. The hist-
ology results were analyzed by a pathologist on a single-
blind basis. For tumor necrosis evaluation on H&E stained
slides, homogenous staining in pink or pale color without
cellular profiles/outline were considered necrotic cells,
while cellular profiles/outlines with dark blue nuclei were
considered healthy cells.
Statistics
Statistical software used for data analysis and presenta-
tion was SAS 9.3 (SAS Institute), Prism 5 (GraphPad
Software), and Excel 11 (Microsoft). Binding curves were
calculated and presented using Prism 5 nonlinear reg-
ression least squares fit sigmoidal dose-response variable
slope (also known as four-parameter dose-response)
curves. Comparisons between different treatment groups
in HUVEC proliferation was performed using a two-way
analysis of variance (ANOVA), which included the main
effects of treatment group and log10 concentration, as
well as the treatment group x log10 concentration inter-
action. Upon finding a significant interaction effect, sep-
arate one-way ANOVA comparisons were carried out at
each concentration. If a significant difference was found,
then Tukey’s multiple comparisons were used. Compari-
sons between different treatment groups in tube forma-
tion by one-way ANOVA provided a F-test with a small
P value (P = 0.0015) supporting subsequent Tukey’s mul-
tiple comparison test. Comparisons between control (ve-
hicle-treated) and different treatment groups for inhibition
of zebrafish angiogenesis were made by Dunnett’s multiple
comparison test. In vivo tumor volumes and weights were
expressed as mean ± standard error of the mean or geo-
metric mean with 95% confidence interval. Comparisons
between different in vivo treatments and control PBS
treated mice for changes in tumor weights were made by
Mann-Whitney two-tailed test. For tumor volume, re-
peated measures (RM) ANOVA with a mixed models ap-
proach was used to determine if the treatment groups
behaved differently across time (i.e. the “group x time”
interaction). A log10 transformation of tumor volume was
used to satisfy the required underlying assumptions of this
statistical model. Since graphical analysis and theoretical
considerations suggest that tumor volume grows logarith-
mically, such that its rate of growth decreases over time, a
log10transformation was applied to day (specifically, log10of
Day +1), and included as a linear main effect, as well as in
the interaction term with group. The model contained one
repeated “within subjects” factor of time, a “between
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interaction. Both group and time were considered fixed ef-
fects in each of the RM ANOVA models, as necessarily
was, the group x time interaction. Upon finding a signifi-
cant difference, interest only focused on the comparison of
the treatment groups to control (PBS), but not amongst
each other. To calculate the statistical significance of treat-
ments on TGI%, we calculated the ratio of tumor volume
at Day 35 relative to Day 0 for each mouse, followed by a
log transformation of this ratio to achieve normality (log
Day35/Day0), which is analytically equivalent to looking at
percent change in tumor volume, but is more suited to
conventional analysis. ANOVA was then used to compare
the mean log ratios with the Student-Newman-Keuls test
to make multiple comparisons. P < 0.05 was considered
significant. For CD31 staining of tumor sections, only
group descriptive statistics were calculated. No inferential
statistical comparisons were performed since the sample
size was so small (n = 3).
Results
Engineering and production of HB-002.1
It has been documented that the second Ig-like domain
(D2) of human VEGFR1 (Flt1[2]) is critical to VEGF
binding [32], however the purified Flt1[2] fused with FcLS VEGFR1-D2
HB-002.1
Flt1(2)-Fc
N-Flank (5aa) C-Flank (2aa)
A.
B. C.




























Figure 1 Engineering and production of HB-002.1. (A) Diagram of HB-0
consisting of the D2 domain only fused with the Fc portion of human IgG
5' and 3' flanking region respectively. Signal peptide derived from the heav
SDS-PAGE gel analysis. Three proteins were included in the analysis: HB-002
each protein were loaded under reducing and non-reducing conditions. (C
1 μg of hIgG-Fc were resolved on 10% SDS-PAGE gels under reducing (R) or n
membrane, and probed with Fc-specific (C) or VEGFR1-specific (D) antibody (did not bind to VEGF at all, and neither did truncated
protein containing the first 2 domains (Flt1[1,2]) or that
containing domains 2 and 3 (Flt1[2,3]) [32]. Only protein
containing domains 1-3 had full VEGF binding activity
comparable to that of the whole extracellular portion of
wild type VEGFR1. This phenomenon was confirmed as
well by Barleon et al [36], revealing the requirement of
VEGF binding for the first three Ig-like domains. Based on
these studies, we designed the HB-002.1 protein in which 5
flanking amino acids (S129-R133) at the N-terminal and 2
amino acids (N227, T228) at the C-terminal of the D2 do-
main were included with D2 (Figure 1A). The D2 domain-
only (Flt1[2]-Fc) was also expressed as a control for VEGF
binding assay.
The HB-002.1 and Flt1[2]-Fc proteins were produced
in CHO cells upon transfection with the corresponding
construct. The secreted proteins were purified and
resolved in 10% SDS-PAGE gels showing MWs of HB-
002.1 and Flt1[2]-Fc at ~110 kDa in non-reducing
conditions, and ~45 kDa in reducing conditions (Figure 1B),
both relatively larger than the calculated MW, which
is most likely due to glycosylation since there are
two N-linked glycosylation sites in the D2 domain.
Bevacizumab resolved in the correct MW positions
(Figure 1B).hIgG1-Fc
D.
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on-reducing (NR) conditions, transferred to a polyvinylidene difluoride
Ab). For comparison, protein MW size markers are shown in kDa.
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was performed using antibodies specific for Fc (Figure 1C)
or VEGFR1 (Figure 1D), showing specific bands for each
specified portion of the protein at different protein loading
amounts.
HB-002.1 has strong binding affinity to VEGF-A
HB-002.1 was first analyzed for its binding affinity to
VEGF-A and compared with that of Flt1[2]-Fc and beva-
cizumab. The data showed that HB-002.1 had a high af-




















































Figure 2 Target binding activity of HB-002.1. Target binding activity of int
to VEGF-A was compared to bevacizumab and Flt1(2). hIgG-Fc was used as n
with rhVEGFR1-Fc. (D) Kinetic binding affinity was measured by equilibrium b
incubation of 0.5 nM of HB-002.1 or bevacizumab with varying amounts of VE
(D) or not deglycosylated (ND) was separated by SDS-PAGE under reducing o
Brilliant Blue. (F) VEGF-A binding affinity was compared between intact (non-dof 24 pM, which was 3-fold higher than that of bevacizu-
mab (EC50 = 72 pM) (Figure 2A). As expected, Flt1[2]-Fc
only had a minimal binding activity to VEGF-A, con-
firming a binding requirement for the flanking sequence.
Binding activity of HB-002.1 to VEGF-B and PIGF was
also investigated by ELISA, showing a modest binding to
VEGF-B (Figure 2B) but low binding to PIGF (Figure 2C).
To determine the target-binding kinetics of HB-002.1,
equilibrium binding assays were performed in which
varying amounts of VEGF-A were mixed with 0.5 nM of
HB-002.1 or bevacizumab, and the unbound HB-002.1E.
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egative control. (B-C) Binding to VEGF-B (B) and PIGF (C) was compared
inding assays that measures unbound HB-002.1 or bevacizumab after
GF-165. (E) HB-002.1 deglycosylated by treatment with N-glycosidase F
r non-reducing conditions and visualized by staining with Coomassie
igested) and deglycosylated (digested) HB-002.1.
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coated plate, revealing that HB-002.1 displays an equilib-
rium dissociation constant (KD) of 180 pM, whereas bev-
acizumab has a KD of 890 pM (Figure 2D).
Since two different-sized bands were observed both in
SDS-PAGE gels and in Western blots, we wondered if
this was due to N-linked glycosylation and if this gly-
cosylation might have an impact on VEGF binding. To
address these questions, HB-002.1 protein was digested
with N-glycosidase F and then resolved in 10% SDS-
PAGE gels, which showed a single band under reducing
conditions and a smaller size single band under non-
reducing conditions when compared to that of non-
digested parental protein (Figure 2E). This confirmed
our hypothesis that the doublet bands were due to N-
linked glycosylation. The digested protein retained simi-
lar VEGF-binding activity to that of parental protein
(Figure 2F), indicating glycosylation is not essential for
high affinity binding, which is consistent with the report
by Barleon et al [36].
HB-002.1 dose-dependently inhibited VEGF-induced
VEGFR2 phosphorylation, HUVEC proliferation and tube
formation
Due to the strong VEGF binding affinity, we anticipated
that HB-002.1 must also have strong blocking activity
against VEGF-induced VEGFR2 phosphorylation as well
as the resulting cell proliferation and tube formation. As
shown in Figure 3A, while strong phosphorylation was
observed with VEGF addition and VEGF plus hIgG, the
induced phosphorylation was sequentially diminished
following addition of sequentially increasing amounts of
HB-002.1, which is comparable to that of bevacizumab
showing a dose-dependent inhibition of VEGFR2 phos-
phorylation (Tyr951/1175) in HUVECs [37].
Comparisons between different treatment groups in
HUVEC proliferation (Figure 3B) by two-way analysis of
variance (ANOVA) provided a F-test with a small P value
(P < 0.0004) supporting subsequent evaluation for differ-
ences among treatment groups. Significant inhibition, as
compared to hIgG-Fc, in VEGF-induced HUVEC proli-
feration was observed in a dose-dependent manner for
HB-002.1 (P < 0.05 at all except lowest dose), which was
comparable to that of bevacizumab (P < 0.05 at all doses)
(Figure 3B). The same phenomenon was also observed for
VEGF-induced tube formation (Figure 3C, D), for which
HB-002.1 had a significant and comparable inhibition to
that of bevacizumab (P < 0.05) as compared to hIgG, sug-
gesting a strong blocking activity of HB-002.1 in VEGF-
mediated cell biological activity.
HB-002.1 dose-dependently inhibited in vivo angiogenesis
Using a transgenic zebrafish embryonic angiogenesis model
[35], the impact of HB-002.1 on in vivo angiogenesis wasinvestigated and showed a dramatic reduction in number
of SIVs. While 7-8 SIVs were usually observed in zebrafish
at 72 hpf (Figure 4A), a decreased number of SIVs was ob-
served when treated with HB-002.1 (Figure 4B). The level
of inhibition versus vehicle group reached 7.5 (±3.5) %
(P > 0.05), 15.2 (±3.3) % (P < 0.01), and 21.4 (±2.4) %
(P < 0.001) for HB-002.1 at the doses of 4.4, 14.7, 44 ng, re-
spectively. Because bevacizumab specifically binds human
VEGF and its activity against zebrafish VEGF is not known,
a broad spectrum angiogenesis inhibitor, endostatin,
known to inhibit angiogenesis in this model [38], was used
as a positive control showing a 9.7 (±2.8) % and 20.1 (±2.6)
% inhibition at the dose of 44 and 100 ng respectively
(Figure 4B). These results suggest a strong angiogenesis
inhibition activity for HB-002.1.
HB-002.1 has an excellent pharmacokinetic profile
HB-002.1 has a much smaller molecular mass than
current VEGF inhibitors, bevacizumab and aflibercept
(~80 vs. ~160 and ~110 kDa, respectively), thus it might
have a shorter half-life and worse PK profile compared
to these drugs. To address these questions, 2.5 mg/kg of
HB-002.1 were injected s.c. into mice (n = 16) and plasma
taken at different time points post-injection were analyzed
for HB-002.1 levels by ELISA. The results indicated that
HB-002.1 has a half-life of 5 days (Table 1), similar to that
of therapeutic antibodies, such as bevacizumab (~6 days
after 9.3 mg/kg s.c. injection) [39], and Fc-fusion pro-
teins [24]. Furthermore, HB-002.1 has additional excellent
PK properties, with a maximal concentration (Cmax) of
20.27 μg/ml, mean residence time (MRT) of 7.5 days, and
total area under the curve concentration (AUC) of
81.46 μg · days/ml (Table 1). This is comparable to that
observed for therapeutic antibody, bevacizumab, starting
at a higher dose (9.3 mg/kg), with a Cmax of 74.1 μg/ml,
MRT of 8.74 days, and an AUC of 682 μg · days/ml
[39,40]. Interestingly, HB-002.1 PK properties are better
than that published for therapeutic fusion protein, despite
aflibercept starting at a higher dose (4 mg/kg), with a Cmax
of 16 μg/ml and an AUC of 36.28 μg · days/ml (Table 2)
[24]. Considering the lower isoelectric point (pI = 6.7) of
HB-002.1 compared to pI = 7.6 and 8.82 for bevacizumab
[37] and aflibercept [24], respectively (Table 2) and smaller
MW of HB-002.1, the excellent PK properties may be due
to better tissue penetration of the protein.
HB-002.1 exhibited robust in vivo anti-tumor activity
The anti-tumor activity of HB-002.1 was evaluated in two
different tumor models, Colo-205 and A549, representing
human colorectal cancer and lung cancer respectively.
BALB/c nude mice bearing these xenograft tumors were
treated with HB-002.1 as well as control drugs by i.p. in-
jection, twice a week, for up to four weeks. Tumor volume




Figure 3 (See legend on next page.)
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Figure 3 In vitro biological activity. (A) HB-002.1 inhibited VEGF-induced VEGFR2 phosphorylation as revealed with immunoblotting assay. This
experiment was repeated three times, all showing a similar pattern of inhibition in VEGFR2 phosphorylation. (B) Inhibition of VEGF-induced HUVEC
cell proliferation was analyzed with the CCK-8 kit, a colormetric assay. Assay was repeated three times with duplicate wells for each concentration.
Representative assay is shown. Significant differences between HB-002.1 and hIgG-Fc (P < 0.05 at all except lowest dose), and bevacizumab and
hIgG-Fc (P < 0.05 at all doses) were observed. Bevacizumab and hIgG-Fc was used as positive and negative controls, respectively. (C) Representative
microscopic images of HUVEC tube formation in Matrigel are shown for medium alone, or for medium plus VEGF with or without HB-002.1,
Bevacizumab, or hIgG. (D) Tube formation was quantified by counting the total vessel length per field. Data were collected from duplicate
wells (mean ± standard deviation). Statistical significance was evaluated by ANOVA and Tukey’s multiple comparison test. Differences between
Medium versus VEGF and VEGF + HB-002.1 versus VEGF + Bevacizumab were not significant (NS). Differences between VEGF + HB-002.1 or
VEGF + Bevacizumab versus Medium or VEGF + hIgG were significantly different (P < 0.05).
Liu et al. BMC Cancer  (2015) 15:170 Page 9 of 14groups. In the Colo-205 xenograft model, HB-002.1 was
compared to doxorubicin, a potent tumor chemothera-
peutic drug that has widespread use clinically and has
demonstrated efficacy in several human tumor xenograft
models [41-43]. Compared to the PBS vehicle group, treat-
ment with the positive control drug, doxorubicin, at
3 mg/kg by single bolus i.p. injection slightly inhibited the
tumor growth (TGI% = 19.78) (Figure 5A), while treatment
with HB-002.1 at 5 or 20 mg/kg i.p. twice weekly showed a
significant tumor growth inhibition, as indicated by the
decrease in tumor volume (TGI%= 93.17 at 5 mg/kg,
TGI% = 93.04 at 20 mg/kg, P < 0.0001) (Figure 5A) and















Figure 4 In vivo angiogenesis inhibition. (A) Subintestinal vessels (SIVs)
(4.4, 14.7, 44 ng) (left) was injected into the blood flow during embryogeni
included in the study as positive controls (right). Representative Images fro
to the number of SIVs in each group.combination therapy of HB-002.1 with doxorubicin did
not show any synergistic increase in efficacy, being equiva-
lent to HB-002.1 treatment alone (Figure 5A-B). Thus,
promisingly, even at the low dose (5 mg/kg), HB-002.1
treatment alone still reached maximal inhibitory effect in
this model, whereas bevacizumab was reported to only
reach TGI%= 55 at the dose of 4.0 mg/kg [44], suggesting
a robust anti-tumor activity for HB002.1.
To determine an effective dosing regimen of HB-
002.1, three doses were applied to the Colo-205 model,
which in comparison to PBS, showed a TGI% on day 28
of 55, 78.2, 82.1 at doses of 1.0, 3.0, and 5.0 mg/kg, re-












under normal conditions are shown. (B) HB-002.1 at different doses
c development of zebrafish. Endostatin at two doses (44, 100 ng) was
m one of the ten zebra fishes in each group are shown. Arrows point
Table 1 Pharmacokinetic parameters of HB-002.1
AUC (g · days/ml) MRT (hr) T1/2 (hr) Cmax (μg/ml)
81.46 180 120 20.27
Note: AUC, area under the curve concentration; MRT, mean.
residence time; T1/2, half-life; Cmax: maximal concentration.
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at doses of 1.2, 2.5, and 4.0 mg/kg, respectively, in the
same model [44]. Additionally, the TGI% for aflibercept
at a much higher dose of 25 mg/kg was reported to be
only 62-75 [41]. Tumor weight at the end of the study
also showed a dramatic and dose-dependent decrease in
the HB-002.1 treated group (Figure 5D, 1.0 (P = 0.0004),
3.0 and 5.0 (P = 0.0002) mg/kg dose). These studies
clearly revealed that HB-002.1 has remarkable anti-
tumor activity, suggesting that HB-002.1 may be a po-
tential alternative therapy for colorectal cancer.
The anti-tumor activity of HB-002.1 was also evalu-
ated in the A549 xenograft model, and compared in par-
allel to that of bevacizumab, for two different dosages (5,
20 mg/kg). While bevacizumab showed a similar but
dramatic inhibitory effect at both doses, similar to that
previously reported [45], the inhibition was more pro-
nounced for HB-002.1 even at the low dose (5 mg/kg)
(Figure 4E-F). When compared to that treated with PBS,
the TGI% was 78.02 and 84.71 for HB-002.1 at 5 and
20 mg/kg, respectively, which was significantly better
than bevacizumab at the same doses, 64.46 and 67.55
TGI%, respectively (Table 3).
HB-002.1 induced tumor growth inhibition is associated
with decreased microvessel density and increased
necrosis of tumor cells
To determine whether the inhibitory effect of HB-002.1
on tumor growth was associated with angiogenesis inhib-
ition in tumor tissues as a result of VEGF blockade,
microvessel density was analyzed by staining tumor tissue
sections with CD31-specific antibody. Treatments with
5 mg/kg of HB-002.1 inhibited formation of CD31+
microvessels when compared to that of the vehicle group
in the Colo-205 or A549 xenograft models (Figure 6,
Table 4). This inhibition was quantified by measuring theTable 2 Comparison of selected PK parameters among VEGF
Inhibitor pI Dose (mg/kg)
HB-002.1 6.7 2.5
Bevacizumab 7.6 9.3
Parental VEGF-Trap 9.4 4.0
VEGF-TRAPΔB1 9.1 4.0
VEGF-TRAPΔB2 8.9 4.0
Aflibercept 8.82 4.0percentage of positive CD31 staining area against the total
tumor area by the visual approximation technique (1.9%
for HB-002.1 vs. 6.2% for PBS in the Colo-205 model;
0.7% for HB-002.1 vs. 7.1% for PBS in the A549 model)
(Table 4). Promisingly, HB-002.1 showed a more potent
effect on CD31+ vessel formation than that for doxorubi-
cin in the Colo-205 model and that for bevacizumab in
the A549 model (Figure 6, Table 4). This inhibition of
microvessel formation in these models is similar to that
reported by others for bevacizumab and aflibercept
[41,44,45].
To confirm that tumor cell necrosis resulted because
of a decreased nutritional supply, H&E staining analysis
was conducted on tumors removed at the end of the
studies. As shown in Figure 7A-B, while little tumor ne-
crosis was observed in vehicle-treated tumors, large re-
gions of necrosis, as exhibited by decreased or absent
hematoxylin-stained (blue) tumor cell nuclei and disor-
ganized cell outlines, were observed in HB-002.1-treated
tumors. This is comparable to that described for bevaci-
zumab [45] and aflibercept [41].
Discussion and conclusion
In the current study, we engineered a new smaller-sized
recombinant VEGF-inhibiting Fc-fusion protein, HB-
002.1 (Figure 1), which had an excellent VEGF-binding
activity (Figure 2) and PK profile (Tables 1 and 2) com-
parable or better than the current generation of VEGF-
inhibiting drugs. This translated into excellent in vivo
anti-tumor efficacy, as shown by its superior therapeutic
efficacy as compared to bevacizumab in the A549 xeno-
graft model (Figure 5E-F, Table 3). Even at low dose
(5 mg/kg), the inhibition mediated by HB-002.1 was still
two-fold better than that of bevacizumab at high dose
(20 mg/kg), although the better efficacy could be par-
tially contributed by HB-002.1 cross-reaction with
mouse VEGF, which does not occur with bevacizumab.
More promisingly, HB-002.1 still reached 50% inhibition
of tumor growth in the Colo-205 model at a dose as low
as 1 mg/kg, suggesting a robust anti-tumor activity for
HB-002.1 (Figure 5C).
Achieving effective concentrations within solid tumor
masses has been challenging for large molecule drugsinhibitors
Cmax (μg/ml) AUC (μg · days/ml) Reference








Figure 5 In vivo efficacy study. (A-B) HB-002.1 treatment even at low dose (5 mg/kg) reached maximal inhibition of tumor growth in Colo-205 s.c.
xenograft model (n = 10 for each group) (A) P < 0.0001 versus PBS treatment for tumor volume over time. (B) P = 0.0002 versus PBS for tumor
weight at time of sacrifice. Treatment was started when tumor volume reached to 150-200 mm3, twice a week, through i.p. injection. (C-D) In
Colo-205 xenograft model (n = 10 for each group), varying amounts of HB-002.1 (1, 3, 5 mg/kg) were tested on effect on tumor growth. Significant
tumor growth inhibition was observed in the lowest dose (1 mg/kg, P < 0.0001 for tumor volume and P = 0.0004 for tumor weight versus PBS). (E-F)
Therapeutic efficacy of HB-002.1 in A549 xenograft model (n = 10 for each group) was analyzed and compared with that of bevacizumab at doses of 5,
20 mg/kg. HB-002.1 at low dose (5 mg/kg) exhibited superior efficacy than bevacizumab at high dose (20 mg/kg) (TGI% = 78.02 for HB-002.1, versus
67.55 for bevacizumab) (Table 3).
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geted area of the body are ideal parameters for large
molecule drugs to reach optimal therapeutic efficacy. It
has been known that the impact factors on penetration,
retention, as well as other PK properties, include mo-
lecular size, charge, valence, and target binding affinity.
For a given protein drug, the rate of diffusion through
tumors is inversely correlated to the molecular weight
[47,48]. scFv fragments diffuse approximately 6 times
faster than IgG due to their smaller size. However pro-
teins with molecular mass less than 60 kDa, which is theTable 3 Tumor growth inhibition in A549 xenograft model
Drugs Mean Tumor Volume Growth inhi
HB-002.1, 5 mg/kg 2.72 (2.51-2.91) 78.02
HB-002.1, 20 mg/kg 1.89 (1.66-2.16) 84.71
Bevacizumab, 5 mg/kg 4.40 (3.59-5.40) 64.46
Bevacizumab, 20 mg/kg 4.02 (3.36-4.81) 67.55
PBS 12.38 (9.87-15.54) 0.00
Sample size = 10 for each group.
Mean Tumor Volume = geometric mean with 95% confidence interval in parentheses.
data that best modeled tumor volume growth.
P value was calculated as described in Methods.
P value vs Bevacizumab is compared to same dose of HB-002.1.
NA = not applicable.threshold for glomerular filtration, will be subject to
quick renal clearance resulting in shorter half-lives.
Molecular charge affects tumor distribution substan-
tially. The defined pI range for optimal tumor penetration
is between 5 and 9 [49]; out of this range, therapeutic pro-
teins are prone to immobilization by electrostatic interac-
tions with the vascular endothelium and/or ECM [49].
Tumors have disordered tissues with regard to vascula-
ture, interstitial fluid pressure, cell density, tissue structure
and composition, and ECM components [50]. Tumor






Geometric mean is shown because statistical analyses utilized log-transformed
A. 
PBS Dox, 3mg/kg, single dose
CD31 staining (Colo-205)
HB-002.1, 5mg/kg





Figure 6 Inhibition of tumor angiogenesis. Tumor angiogenesis analysis was performed by CD31 staining. Significant reduction in new blood
vessel formation (black arrows) was observed in HB-002.1 treated Colo-205 (A) as well as A549 (B) tumors, respectively. Representative fields of
CD31 staining in tumors treated with PBS (left) or doxorubicin (upper middle) or HB-002.1 (right) are shown at 40x magnification (40X).
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adhered to highly negatively charged proteoglycans found
in the ECM. For example, the parental VEGF-Trap mol-
ecule before aflibercept had a high pI (9.4) and poor PK
properties, with a Cmax of only 0.05 μg/ml and total AUC
of 0.04 μg × days/ml (Table 2) [24]. Realizing the effec-
tiveness of parental VEGF-Trap may be affected by its
high pI, basic amino acids were removed to create VEGF-
TrapΔB1, followed by removal of additional basic amino
acids to create VEGF-TrapΔB2, and finally replacing an en-
tire protein domain with a less basic protein domain to
create aflibercept (Table 2) [24]. This molecular engineer-
ing caused a steady reduction of the pI from 9.4 to 8.82Table 4 Percentage of positive CD31 staining in tumor
section
Group % of CD31 in Colo-205 % of CD31 in A549
PBS 6.2 (+/- 2.1) 7.1 (+/-3.2)
Doxorubicin, 3 mg/kg 6.8 (+/- 3.6) not done
HB-002.1, 5 mg/kg 1.9 (+/- 0.9) 0.7 (+/- 0.2)
Bevacizumab, 20 mg/kg not done 3.9 (+/- 2.9)
Note: Average (+/- SEM) from 3 samples in each group is shown.and resulted in a concomitant improvement in the PK
profile, with a final Cmax of 16 μg/ml and an AUC of
36.28 μg × days/ml (Table 2) [24]. Thus, for a given
therapeutic protein, the ideal pI should be near phy-
siologic pH as molecules with neutral charge diffuse
more readily.
To our knowledge, the robust anti-tumor efficacy of
HB-002.1 seen in xenograft models and superior efficacy
compared to bevacizumab could be attributed to three
reasons. The first reason is the molecular weight which
is only ~80 kDa, much smaller than both aflibercept
(~110 kDa) and bevacizumab (~160 kDa). The relatively
small size makes it easier to penetrate into tumor tissues
and accumulate, resulting in better bioavailability. The
second reason is the pI of HB-002.1 is near neutral,
which is the most ideal pI for a recombinant protein as
inverse correlation between the pI and the PK profile
has been seen with aflibercept (Table 4) [24]. The third
reason might be due to cross reactivity of HB-002.1 with
mouse VEGF, which is not seen with bevacizumab.
In conclusion, we have designed a novel recombinant
VEGF blocker designated as HB-002.1, which has an ex-
cellent PK profile and robust anti-tumor activity as
A. 







Figure 7 H&E staining analysis. H&E staining for HB-002.1 treated tumor sections at low dose (5 mg/kg) was presented and compared to that
of PBS treated group. Large regions of tumor necrosis were observed in Colo-205 (A) as well as A549 (B) tumor sections respectively. Representative
fields of H&E staining are shown at 4x (A) and 20x (B) magnification for Colo-205 and A549 tumor sections, respectively.
Liu et al. BMC Cancer  (2015) 15:170 Page 13 of 14compared to the current generation of VEGF blockers.
The accumulated research data exhibited in this report
warrant further preclinical analysis of HB-002.1, which
will set the basis for clinical investigation.
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